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Abstract. The tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) is a potent inducer of apoptosis in
many cancer cells. However, a significant proportion of
tumours are TRAIL-resistant erecting a major hurdle for a
successful TRAIL-based treatment regimen in the future. In
this context, it would be a major advantage to be able to
identify the tumours that respond to TRAIL. The existence of
two apoptosis-inducing receptors (TRAIL-R1 and TRAIL-R2)
and two receptors that cannot transmit an apoptotic signal
and have an inhibitory function (TRAIL-R3 and TRAIL-R4)
make TRAIL signalling complicated. We analysed the surface
expression of all four membrane-bound TRAIL receptors in
cancer cell lines of various origin and primary cancer and
normal cells and found a good correlation between TRAIL-
sensitivity and the expression of TRAIL-R1 alone, but an
even better correlation when a ratio of TRAIL-R1/TRAIL-
R3+TRAIL-R4 was analysed. Experimental overexpression of
TRAIL-R1 alone or in combination with TRAIL-R4 in PANC-1
cells confirmed our correlation results. Similar to the surface
expression-apoptosis correlation analysis we found a high
correlation between TRAIL-sensitivity and the mRNA level
ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4. A value of <0.85
for the ratio predicted TRAIL resistance in both protein and
RNA analysis. Hence, TRAIL receptor RNA expression
analysis by real-time PCR might be a feasible approach to
predict possible TRAIL-responses in individual tumour
samples.
Introduction
Tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL, also known as Apo-2L) is a member of the tumour
necrosis factor family of cytokines and can selectively
induce apoptosis in many cancer cells but not in most normal
cells and has been proposed as a potential anti-tumour agent
(1-5). TRAIL can bind to four membrane-bound death
receptors (TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4,
also known as DR4, DR5, DcR1 and DcR2, respectively).
Both TRAIL-R1 and TRAIL-R2 contain a conserved
cytoplasmic region called the death-domain that is required
for TRAIL induced apoptosis (1,6,7). Upon activation of
TRAIL-R1 and TRAIL-R2 the adaptor protein Fas-
associated death domain (FADD) is recruited to the
receptors, which, along with procaspase-8, forms the death-
inducing signalling complex (DISC) (8). Active caspase-8,
the apical caspase in death receptor-induced apoptosis, can
then activate effector caspases, such as caspase-3, which in
turn cleave many cellular substrates resulting in the
biochemical and morphological features characteristic of
apoptosis (9,10). However, TRAIL-R3 lacks an intracellular
domain and TRAIL-R4 only contains a truncated death-
domain. Thus, TRAIL-R3 and TRAIL-R4 may protect cells
from TRAIL-induced apoptosis by acting as decoy receptors
(6,11).
While TRAIL has shown remarkable promise as an anti-
cancer agent, a significant fraction of tumour cells display
TRAIL resistance (12-17). Different explanations have been
suggested for this resistance. One hypothesis suggests the
presence of decoy receptors (TRAIL-R3 and TRAIL-R4) that
compete for binding to TRAIL (11,18). The internal signalling
pathway causing apoptosis after TRAIL treatment has been
studied in detail, but the specific functions of the different
TRAIL receptors on the surface of cancer cells and possible
correlations with TRAIL responses are far less clear. Several
studies (19-24) suggest that regulation of TRAIL-induced
apoptosis is dependent on the expression of its various
receptors. Therefore, the understanding of the regulation and
function of each receptor during tumour progression is a
prerequisite for the therapeutic application of TRAIL and
might help to predict TRAIL responses of individual tumours,
allowing for the more efficient use of TRAIL in clinical trials
and beyond.
In the present study, we found a high correlation of the
expression level ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4
to TRAIL sensitivity. Because of this high correlation of the
TRAIL receptor expression ratio and apoptosis, we propose
this ratio as a potentially useful marker for predicting TRAIL
responsiveness of tumours.
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Materials and methods
Reagents and cell lines. All reagents were purchased from
Sigma (St. Louis, MO) unless otherwise stated. Human soluble
recombinant TRAIL was purchased from R&D Systems
(Minneapolis, MN). The human cell lines PANC-1, Hek293
and HeLa were maintained in Dulbecco's modified Eagle's
medium (DMEM). The cell line Caki-2, A549 and DLD-1
were cultured in RPMI-1640 medium. Caco-2 and the
HCT116 were cultured in McCoy's medium. Media were
supplemented with 10% fetal calf serum (FCS), 200 U/ml
penicillin (P) and 200 μg/ml streptomycin (S). FCS and P/S
were purchased from Biochrom (Berlin, Germany). All cell
lines were cultured at 37˚C and 5% CO2. Colorectal carcinoma
primary cells were collected from patients during surgery
from University Hospital Galway. Samples were dissected
into 1x1x1 mm pieces, immersed in a 10-fold volume of
RPMI-1640 containing 1.5 mg/ml collagenase, 5% FCS and
antibiotics and then incubated at 37˚C overnight. The
suspension containing released cells was then centrifuged at
150 x g for 5 min. The precipitated cells were resuspended in
culture medium [RPMI-1640, 25 mM Hepes, 5% FCS, 50 nM
hydrocortisone, 20 μg/ml insulin, 10 μg/ml transferrin, 25 nM
sodium selenite, 1 ng/ml epidermal growth factor (EGF),
10 μM ethanolamine, 10 μM phosphorylethanolamine, 100 pM
triiodothyronine and 0.5 mM sodium pyruvate] and seeded
into collagen-coated culture flasks. MSCs were obtained
through the Regenerative Medicine Institute at the National
University of Ireland, Galway and grown, characterised and
maintained, as previously described (25).
Measurement of apoptosis. For the detection of apoptotic cell
death, standard DNA fragmentation assays according to
Nicoletti et al (26) and Braeuer et al (27) were used. Untreated
cells were taken as reference to calculate specific apoptosis
by subtraction of the basal apoptosis values from the levels
of treated cells.
Determination of the surface TRAIL receptor expression.
TRAIL-R1 (HS 101), TRAIL-R2 (HS 201), TRAIL-R3
(HS 301) and TRAIL-R4 (HS 402) monoclonal antibodies
(Alexis, Lausen, Switzerland) were used for FACS analyses
of surface receptor expression, as previously described (28).
Unspecific murine IgG1 was used as control for unspecific
staining (isotype control).
Quantitative real-time PCR assays. Gene quantification was
performed with a LightCycler (Roche Diagnostics, Mannheim,
Germany) real-time PCR system. Total RNA was prepared
from subconfluent cells using the RNeasy mini kit from
Qiagen (Hilden, Germany). The primer-probe sets were
designed with the GeneFisher software. Porphobilinogen
Deaminase (PBGD) real-time PCR was used to normalise
TRAIL-receptor data.
Statistical analyses. If not stated, three independent
experiments were performed in triplicate. Experimental values
are expressed as mean value ± standard error (SE). Linear
regression analyses were performed to examine the correlation
between the resistance to TRAIL and the expression of the
TRAIL receptors. The correlation is expressed as R2. For
significance analyses Student's t-tests, were used and p<0.05
was considered significant and p<0.001 as highly significant.
Results
TRAIL responsiveness varies among different tumour cell lines
and primary (cancer) cells. Solid tumour cell lines of various
tissue origins including colon cancer cell lines (HCT116,
DLD-1, Caco-2), renal cancer cells (Caki-2), non-small lung
cancer cells (A549), cervical cancer cells (HeLa) and pancreatic
cancer cells (PANC-1) were used in this study. Furthermore,
primary colon carcinoma cells (FMC), human mesenchymal
stem cells (MSCs), human primary fibroblasts and transformed
embryonic kidney cells (Hek293) were analysed. To evaluate
the cell killing effect of TRAIL on these cells, they were
treated with various concentrations (2, 5 and 10 ng/ml) of
soluble recombinant TRAIL for 24 h, after which the apoptotic
response was measured (Fig. 1). Two cell lines (Caki-2,
DLD-1) were highly sensitive to TRAIL-mediated cell death
with ≥70% of the cells killed when challenged with 10 ng/ml of
TRAIL. HeLa and HCT116 cells were sensitive with ~50%
of the cells killed. Hek293 cells were defined as moderate
sensitive with apoptosis rates of 10-20%. The other cell types
(FMC, hMSC, fibroblasts, Caco-2, PANC-1, A549) were
resistant to TRAIL-induced apoptosis. To see if the different
TRAIL responsiveness could be attributed to their TRAIL-
receptor expression profiles, we analysed the protein
expression of the four membrane-bound TRAIL receptors.
TRAIL responsiveness is correlated to the ratio of expression
levels of TRAIL-1 and the sum of TRAIL-R3 and TRAIL-R4.
In order to determine whether there is a correlation between
TRAIL responsiveness and the expression levels of the four
TRAIL-receptors, the surface protein expression levels of the
four membrane-bound TRAIL receptors were analysed
(Fig. 2A). Surface protein levels were determined by FACS
measurements after staining with specific TRAIL receptor
antibodies and a PE-labelled secondary antibody (Fig. 2A).
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Figure 1. The indicated tumour cell lines were treated with 2, 5 and 10 ng/ml
of soluble recombinant TRAIL for 24 h, collected and analyzed for DNA
content by DNA hypodiploidity assay. Percentages of cells with sub-G1
DNA content (= apoptotic cells) are shown.
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We found varying TRAIL-receptor expression profiles, but
TRAIL sensitivity seemed to correlate with the expression of
the apoptosis-activating receptors TRAIL-R1, as the most
sensitive cell lines (DLD-1 and Caki-2) had the highest
expression levels of this receptor and the TRAIL-resistant cell
lines such as PANC-1 showed very low expression levels of
TRAIL-R1. However, A549 and Hek293 cells appeared to
be outliers in this regard. Both cell lines harboured high
TRAIL-R1, but were either TRAIL-resistant (A549) or showed
only moderate TRAIL responsiveness (Hek293). To analyse
this correlation in more detail we performed a regression
analysis between the expression level of TRAIL-R1 and
TRAIL responsiveness (10 ng/ml TRAIL) of the cell lines
tested (Fig. 2B). Despite the two outliers regression analysis
confirmed a good correlation of TRAIL-R1 expression level
with TRAIL responsiveness (Fig. 2B). Next, we tested whether
inclusion of the decoy receptors would improve our regression
analysis. Indeed, we arrived at an even higher correlation
coefficient (R2) using the ratio of TRAIL-R1 and the sum of
the expression levels as expressed in MFI ratios of TRAIL-R3
and TRAIL-R4 (Fig. 2C). Overall, a ratio of ≤0.85 for the MFI
of TRAIL-R1 divided by the sum of the MFIs of TRAIL-R3
+TRAIL-R4 was found to be predictive for TRAIL resistance.
Hence, the expression levels of the apoptosis-activating
receptor TRAIL-R1 in relation to TRAIL-R3 and TRAIL-R4
appears to be predictive for the TRAIL responsiveness of
cancer as well as normal cells.
Overexpression of TRAIL-R1 and TRAIL-R4 in PANC-1
cells. In order to confirm the correlation between the TRAIL
sensitivity and the ratio of TRAIL receptor expression levels,
we generated stable PANC-1 cell lines that overexpressed
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Figure 2. Analyses of the cell surface TRAIL receptor expression. (A) The levels of all four TRAIL receptors (TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4)
were measured by FACS in the indicated cell lines and expressed as MFI ratio. (B) Regression analyses of TRAIL (10 ng/ml) responsiveness as expressed by
apoptosis levels and the expression level of TRAIL-R1 expressed as MFI ratio. The squared correlation coefficient (R2) is 0.8868. (C) This graph shows the
correlation between TRAIL (10 ng/ml) sensitivity as expressed by apoptosis levels and the ratio of TRAIL-R1 MFI and the sum of the MFIs of antagonistic
TRAIL receptors TRAIL-R3 and TRAIL-R4. The squared correlation coefficient (R2) is 0.9701.
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either TRAIL-R1 alone or together with TRAIL-R4. Protein
expression of the TRAIL receptors was measured by FACS
and we established two independent clones (C1, C2) that
overexpressed TRAIL-R1 to different levels (Fig. 3A). C2
was used to concurrently overexpress TRAIL-R4 resulting in
clone 3 (C3) (Fig. 3A). Subsequently, we treated these clones
as well as parental PANC-1 cells with TRAIL and measured
apoptosis. The apoptosis assay revealed that C1 and C2 were
TRAIL-sensitive with apoptosis rates of 35% (C1) to 60%
(C2) (Fig. 3B). In C3 apoptosis was markedly reduced (45%)
as compared to its parental clone C2 (60%) owing to the
moderate overexpression of TRAIL-R4 in C3. Next, we
wanted to test whether these experimentally generated
PANC-1 cell clones would also fit our correlation model.
The correlation diagram including our original cell lines and
primary cells as well as the three PANC-1 clones, C1, C2 and
C3 confirm the relationship between TRAIL responsiveness
and the expression levels of the TRAIL-R1, TRAIL-R3 and
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Figure 3. Analyses of the effect of TRAIL-R1 and TRAIL-R4 overexpression (transgene, tg) on TRAIL responsiveness in pancreatic carcinoma cells PANC-1.
(A) The levels of TRAIL receptors of two PANC-1 stable cells clones that overexpress TRAIL-R1 (C1, C2) and one stable cell clone, derived from C2 that co-
overexpresses TRAIL-R1 and TRAIL-R4 (C3) were measured by FACS and expressed as MFI ratios. (B) Apoptosis assay after TRAIL treatment (10 ng/ml)
from C1, C2 and C3 in comparison to parental PANC-1 cells, used as a control (Ctr). (C) Comparative regression analyses between apoptosis induced by
TRAIL (10 ng/ml) and expression of TRAIL-R1 surface protein (MFI) divided by the sum of the antagonistic TRAIL-R3 and TRAIL-R4 expression (MFI)
including the stable cell lines C1, C2 and C3. The squared correlation coefficient (R2) is 0.9697.
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TRAIL-R4 (Fig. 3C). Hence, it appears possible to use this
model to predict TRAIL sensitivity.
In a clinical setting it would probably be easier and
more reliable to prepare RNA from tissue biopsies than to
perform tissue staining with four different TRAIL receptor
antibodies, while FACS analysis is unlikely to be a feasible
option. Moreover, real-time PCR procedures can be
automated and give rise to quantitative data. Therefore, we
were interested in determining mRNA expression levels of the
TRAIL receptors and compare them to surface protein
expression levels.
Determination of mRNA expression levels of TRAIL receptors
by real-time PCR. Overall, the mRNA expression levels, as
measured by real-time PCR, of the four TRAIL receptors were
comparable to the surface protein expression levels (Fig. 4A).
Again there was a good correlation of TRAIL-R1 expression
and TRAIL sensitivity (Fig. 4B), but the ratio of TRAIL-R1/
(TRAIL-R3+TRAIL-R4) yielded an even better correlation
coefficient (Fig 4C). Again, a factor of <0.85 for MFI
TRAIL-R1/MFI TRAIL-R3+MFI TRAIL-R4 indicated
TRAIL resistance. We conclude that TRAIL responsiveness
is highly correlated to the expression of TRAIL-R1 as well as
TRAIL-R3 and TRAIL-R4 and that quantitative RNA analysis
by real-time PCR is a suitable method to measure and
calculate a coefficient (TRAIL-R1/TRAIL-R3+TRAIL-R4)
that can predict responsiveness to TRAIL.
Discussion
Resistance to TRAIL-induced apoptosis can occur at different
levels in the TRAIL signalling cascade. One important factor
that can lead to TRAIL resistance is the impaired or
dysfunctional expression of TRAIL receptors. For example a
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Figure 4. Real-time PCR analyses of TRAIL receptor expression. (A) The histogram shows the relative transcription units (RTU) of the four TRAIL receptors
in the indicated cell types. (B) Regression analyses of TRAIL-R1 expressed as RTU and TRAIL responsiveness (10 ng/ml). The squared correlation
coefficient (R2) is 0.8885. (C) This diagram shows the correlation between specific apoptosis and the RTU-ratio of TRAIL-R1 expression divided by the sum
of TRAIL-R3 and TRAIL-R4 expression. The squared correlation coefficient (R2) is 0.903.
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death receptor malfunction due to genetic mutations (29,30)
or a lack of TRAIL-R1 and TRAIL-R2 expression (31) have
been implicated in TRAIL resistance. In general, TRAIL
binds to two cell-death-inducing (TRAIL-R1 and TRAIL-R2)
and two decoy receptors (TRAIL-R3 and TRAIL-R4).
However, the role of the decoy receptors in TRAIL-resistance
is controversial. While several studies have highlighted their
importance (24,32-35), others have been unable to find a
correlation between expression of TRAIL-R3 and/or TRAIL-
R4 and TRAIL responsiveness (36-40). The complicating
issue in these studies is that expression of decoy receptors
is not the only molecular mechanism that can explain
TRAIL resistance. In fact, several factors and pathways have
been implicated in the inhibition of TRAIL-induced apoptosis
(41). Thus, even in the absence of decoy receptors cancer
cells can be TRAIL-resistant. Moreover, it appears likely that
the ratio between the two death-inducing receptors on the one
side and the two decoy receptors on the other is more
important than the level of each individual receptor on its
own. Therefore, we set out to investigate the expression of
TRAIL receptors from eleven different cell types including
cancer cell lines, primary colon carcinoma, fibroblastic cells
and human MSCs. We found widely variable expression of
the four TRAIL receptors. Nonetheless, our correlation
analysis of TRAIL-receptor expression levels and TRAIL-
induced apoptosis levels revealed that in cancer cells lines as
well as in primary cells including primary colon cancer cells
the balance between death-inducing (TRAIL-R1) and death-
protecting TRAIL receptors (TRAIL-R3 and TRAIL-R4) is a
determining factor for TRAIL responsiveness. Plotting our
TRAIL receptor ratios (MFI of TRAIL-R1/MFI of TRAIL-R3
+ MFI of TRAIL-R4) against the respective apoptosis levels
we found the value that determines resistance of tumour cells
to TRAIL cells to be <0.85. While it is clear that the TRAIL-
receptor expression profile is not the only determining
factor for TRAIL responses, our approach can identify
tumours that will definitely not benefit from TRAIL
treatment. As we found that measuring TRAIL-receptor
expression by real-time PCR was as good as TRAIL-receptor
stains in our prediction model, real-time PCR analysis could
be developed into a method to predict the tumour
responsiveness to TRAIL.
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